Portfolio
Project 3: Investigating GALR3 as a novel target for the treatment of post-partum depression
Lead: Blacksand Therapeutics, UK Funding Partners: Boehringer Ingelheim Project Launch: 28th June 2022 Project Duration: 6 months Background Post Partum Depression (PPD) is one of the most common, yet under-reported complications of childbirth and affects 13% of women following delivery. Galanin Receptor 3 (GalR3) is a stress and oestrogen-inducible neuropeptide, with numerous strands of evidence linking it […]
Project 2: Investigating NEGR1 as a novel target for the treatment of depression
Lead: University of Trento, Italy Funding Partners: Biogen, J&J, MSD Project Launch: 1st February 2022 Project Duration: 36 months Background NEGR1 is one of the most significant risk genes for the development of major depressive disorder, pointing to brain expression upregulation as the mechanism underlying it’s genetic association. Project Plan The researchers will apply a […]
Project 1: Investigating KALRN as a novel target for the treatment of schizophrenia
Lead Institution: University of Oxford Partner Institution: Earlham Institute Funding Partners: Boehringer Ingelheim & Biogen Project Launch: 1st December 2020 Project Duration: 18 months Background KALRN is thought to play an important role in the regulation of neuronal communication, which is known to be altered in the brains of people with schizophrenia. Restoring this communication […]
